Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of riliprubart in adults with CIDP
MOH_2026-08-13_016985Phase 3Not yet recruiting
- Sponsor
- Sanofi
- Start
- May 2026
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of riliprubart in chronic inflammatory demyelinating polyneuropathy (CIDP), sponsored by Sanofi. Planned start May 2026; status: not yet recruiting.
02
Drugs
riliprubart
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on MOH_2026-08-13_016985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-08-13_016985.